Crossbow Therapeutics Selects First Development Candidate from its Portfolio of Next-Generation T-cell Engagers Directed at Intracellular Cancer Targets Crossbow Therapeutics today announced the nomination of its first development candidate, CBX-250, a T-cell engager for the treatment of myeloid leukemia.

Crossbow Therapeutics Launches with $80 Million in Series A Financing to Advance a Novel Class of Antibody Therapies That Mimic T-Cell Receptors to Treat Cancer Proprietary T-Bolt™ technology dramatically broadens the benefits of immunotherapy by targeting the entire universe of cancer antigens  Company led by proven industry veterans Briggs Morrison,...